key: cord-0890344-njx1rtcm
authors: Hogan, A. B.; Winskill, P.; Watson, O. J.; Walker, P. G. T.; Whittaker, C.; Baguelin, M.; Brazeau, N. F.; Charles, G. D.; Gaythorpe, K. A. M.; Hamlet, A.; Knock, E.; Laydon, D. J.; Lees, J. A.; Lochen, A.; Verity, R.; Whittles, L. K.; Muhib, F.; Hauck, K.; Ferguson, N. M.; Ghani, A. C.
title: Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: a mathematical modelling analysis
date: 2021-03-20
journal: nan
DOI: 10.1101/2021.03.19.21253960
sha: 6326e74b92a1a02f31008365b263f102056b8807
doc_id: 890344
cord_uid: njx1rtcm

The worldwide endeavour to develop safe and effective COVID-19 vaccines has been extraordinary, and vaccination is now underway in many countries. However, the doses available in 2021 are likely to be limited. We extended a mathematical model of SARS-CoV-2 transmission across different country settings to evaluate the public health impact of potential vaccines using WHO-developed target product profiles. We identified optimal vaccine allocation strategies within- and between-countries to maximise averted deaths under constraints on dose supply. We found that the health impact of SARS-CoV-2 vaccination depends on the cumulative population-level infection incidence when vaccination begins, the duration of natural immunity, the trajectory of the epidemic prior to vaccination, and the level of healthcare available to effectively treat those with disease. Within a country we find that for a limited supply (doses for <20% of the population) the optimal strategy is to target the elderly. However, with a larger supply, if vaccination can occur while other interventions are maintained, the optimal strategy switches to targeting key transmitters to indirectly protect the vulnerable. As supply increases, vaccines that reduce or block infection have a greater impact than those that prevent disease alone due to the indirect protection provided to high-risk groups. Given a 2 billion global dose supply in 2021, we find that a strategy in which doses are allocated to countries proportional to population size is close to optimal in averting deaths and aligns with the ethical principles agreed in pandemic preparedness planning.

COVID-19 has caused an unprecedented global public health and economic challenge which will continue to disrupt lives and livelihoods until a preventative intervention, such as a vaccine, becomes widely available. Demand for a vaccine is unparalleled and extraordinary public and private sector efforts have been undertaken to identify vaccine candidates, to conduct clinical trials on compressed timelines and to scale up manufacturing ahead of regulatory approval. To date, 13 vaccines have been approved or authorised for use by individual or groups of countries, and many more vaccine candidates are in development [1] [2] [3] [4] [5] [6] .

Even as some countries begin to introduce approved vaccines, the demand for doses is likely to exceed supply through 2021 due to constraints in manufacturing. Despite the development of international initiatives such as COVAX to share the risks of the research and development process, and to ensure equitable access 7 , political and economic incentives for countries to prioritise national interest remain high -as has already been demonstrated by countries stockpiling treatment supplies and other pharmaceuticals 8, 9 as well as countries signing advanced purchase agreements for individual vaccines.

Four allocation principles, reflected in the current World Health Organization (WHO) global allocation framework 10 , have been identified by bioethicists to guide allocation of scarce resources: (A) that the health benefits of the resource are maximised; (B) that priority is given to those who would be worstoff in the absence of the resource; (C) that individuals in equal circumstances should be treated equally; and (D) that societal benefit is maximised 11, 12 . A key component in achieving principles A and B will be targeting the vaccine to those at highest risk of death. Given the strong age-gradient of risk associated with COVID-19 infection 13 , allocation is likely to be age-targeted. However, to meet principle B, vaccine dose allocation will need to be balanced against both life-expectancy (in order to minimise life-years lost) and the additional variation in the risk of death resulting from, for example, inequitable access to healthcare across the globe. In addition, aligned with principle D, it is likely that any vaccine allocation would also prioritise essential workers such as those providing the frontline health response 14 . Adhering to these principles to derive a fair and optimal allocation strategy, given limited vaccine stocks is far from straightforward. We extend a model of SARS-CoV-2 transmission to explore the public health impact of different vaccine characteristics, epidemic stages, and population-targeting strategies. We apply the model to countries with different levels of income to understand the impact of demographics, societal mixing and health system constraints in overall vaccine benefit. We explore the implications of these characteristics for within-country allocation and global allocation and quantify the maximum public health benefit of different allocation strategies under a range of likely supply constraints, over the time periods 2021 only and 2021-2022.

We extended a previously developed age-structured deterministic SEIR-type compartmental model of SARS-CoV-2 transmission 15 to include vaccination. The model explicitly incorporates the clinical pathway for those requiring hospitalisation, allowing estimates of the need for oxygen support and/or intensive care unit (ICU) support. Transmission depends on age-based contact matrices and a constant transmission rate per contact (in sensitivity analysis we explore reduced transmission from children).

Other risk groups or settings (such as healthcare workers or care homes) are not included. The model was extended to capture loss of naturally acquired immunity by including an additional flow from the recovered state to the susceptible state.

Once vaccination is introduced into a population, we assume that all eligible individuals (depending on the targeting or prioritisation that is applied) are vaccinated at a constant rate, up to a maximum level of coverage. Vaccination prioritisation strategies are modelled by specifying an age disaggregated matrix of coverage targets where rows are ordered prioritisation steps (see Supplementary Information, Section 1.2). Individuals who are susceptible, in the latent period, or recovered (immune) can be vaccinated. The model structure assumes that people who are currently infected do not receive the vaccine, and while this simplification may miss asymptomatic individuals, such people represent a small fraction of the total population at any given time. Vaccinated individuals initially enter a temporary state to capture the delay between receiving the vaccine and being protected before moving into a vaccine-protected state. We assume that protection is partial, with efficacy parameters detailed in Table 1 . Given that the duration of protection for the approved and candidate vaccines is not yet known, we assume that vaccine-induced immunity can either be longterm, one year, or six months, and we model decay in vaccine-induced immunity by moving individuals from the vaccinated and protected state to a further state in which they are again susceptible to infection (unless they acquire immunity through natural infection). Protection against infection only . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2021. ;  https://doi.org/10.1101/2021.03.19.21253960 doi: medRxiv preprint is modelled by reducing the risk of acquiring infection in those who are vaccinated by a constant factor, capturing the fact that vaccines will not give complete protection against infection. Protection against severe disease only is captured by reducing the proportion of cases that are hospitalised. Combined protection (the default setting) assumes protection against infection, with an additional reduction in the risk of severe disease in vaccinated individuals who experience a breakthrough infection.

Additional details of the model are given in the Supplementary Information ( Figure S1 ; Tables S1 and   S2 ).

The open-source model code is available as an R package at https://github.com/mrc-ide/nimue. To aid utility of the modelling framework by policymakers, government agencies and other stakeholders, we additionally developed a user-friendly interface (Box 1). In the interface the model is fitted to country epidemics (see Section 1.4 in Supplementary Information) with these fits updated weekly to reflect rapidly changing epidemic situations. Updates to this interface will incorporate new information that emerges as the pandemic unfolds.

We stratify the global population into four groups, based on the current World Bank 16 classification of high-income countries (HIC), upper-middle-income countries (UMIC), lower-middle-income countries (LMIC) and low-income countries (LIC). Countries are assumed to remain in their current group over the projection horizon. For each income setting, the age distribution of the population and age-based contact patterns are modified to capture epidemiological characteristics of countries in the different income strata. We use the current age distribution for the country with the median GDP in each of the four groups (HIC: Malta; UMIC: Grenada; LMIC: Nicaragua; and LIC: Madagascar) 17 , and age-based contact patterns representative of these settings based on the availability of contact data studies 15 .

Natural history parameters for SARS-CoV-2 infection are based on a review of published estimates and large clinical studies 18, 19 with age-stratified probabilities of requiring hospitalisation and intensive care obtained from a national study of French hospital admissions 20 and the age-stratified infection fatality ratio (IFR) obtained from a recent meta-analysis 21 (Table S2) . The model has been previously validated by using Bayesian methods to fit to country-specific data on COVID-19 deaths ( Figure S2) 22 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.19.21253960 doi: medRxiv preprint higher protection against severe COVID-19 disease, and this is supported by evidence being generated by vaccine implementation in the UK and Israel 3,5,24-27 . The extent to which these candidate vaccines will prevent infection is not fully known, however the phase III Oxford/AstraZeneca study reported efficacy against asymptomatic COVID-19 of 27.3% (95% CI −17.2-54.9) in a preliminary analysis 2 , and evidence from the UK indicates a four-fold reduction in asymptomatic COVID-19 in vaccinated versus unvaccinated healthcare workers, following a single dose of the Pfizer/BioNTech vaccine 28 . Given these results, for our baseline simulations we assume vaccine efficacy against infection of 90%, with an additional 60% efficacy against severe disease for vaccinated individuals who experience breakthrough infection 24 . We further consider 70% efficacy against infection as a sensitivity analysis, which also aligns with the preferred efficacy level in the WHO Target Product Profiles 29 . We also consider scenarios for a vaccine that reduces risk of infection only, with no additional protection against severe disease, and a vaccine that reduces the risk of severe disease only, without reducing the risk of infection. In simulations exploring the potential for lower vaccine efficacy in older age groups, we also consider a scenario where vaccine efficacy in those aged 65 years and older is 50% of that in younger individuals, based on observations from influenza vaccination 30, 31 . We assume an average period between vaccination and protection of 7 days, consistent with observations of increasing antibody and T-cell responses in the phase II data [32] [33] [34] [35] [36] . We assume no partial protection in the period between vaccination and protection. Antibody reversion from natural infection 37 and reinfection 38 has now been reported, and a UK-based study of hospital staff found that prior infection was associated with an 83% lower risk of infection, with a median duration of follow-up of five months 39 . Our baseline runs therefore assume that natural immunity following infection persists for an average of one year, and we additionally explore both six-month and long-term durations in sensitivity analyses, consistent with values identified in the WHO Target Product Profiles 29 . Key parameters are summarised in Table 1, Table S1, and Table S3 .

To evaluate the public health impact of any vaccine, we must consider the epidemic trajectory in the absence of vaccination. However, because of the vastly different experiences between countries in their exposure and response to SARS-CoV-2, considering such counterfactuals is challenging, particularly since testing rates differ markedly and so it can be difficult to accurately assess the current epidemic stages of different countries. Furthermore, whilst vaccination has commenced in some countries, scale-up will occur over a longer period. In the interim, countries will likely continue to implement some level of non-pharmaceutical interventions (NPIs). We do not explicitly model individual NPIs, but instead incorporate the assumed impact of combined NPIs in the estimate of the reproduction number Rt. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint To understand the public health value of the vaccine and consider allocation strategies that do not penalise countries for lacking the capacity to implement NPIs, in our baseline scenario we make the simplifying assumption that the vaccine is introduced while NPIs are in place. This avoids the situation in which our modelled results suggest the vaccine has no impact because the vaccine introduction Our baseline scenarios assume that an initial peak in transmission occurred in the first half of 2020, which is reduced by NPIs, resulting in lower levels of transmission through the remainder of the year ( Figure S3 ). Assuming a mean duration of immunity of one year and for levels of transmission where R0 = 2.5 and Rt1 = 1.1, the simulation results in 11% of the population becoming immune by the end of 2020 in a HIC setting (plausible given seroprevalence surveys to date 23,24 ), and results in 11%, 12%, and 16% immune in UMIC, LMIC and LIC settings respectively ( Figure 1 ; Figure S5 ). We explore additional scenarios with long-term natural immunity, which results in a higher proportion immune at vaccine introduction ( Figure S5 ), and also explore different plausible values of R0 and Rt1, which result in the proportion of the population immune at vaccine introduction varying between 4% and 24% ( Figure S6 ).

For each income setting, we consider two possibilities for health system capacity. The first is that all health systems are unconstrained -and hence that a constant (age-dependent) proportion of infections are hospitalised and receive appropriate care, regardless of the size of the epidemic. This results in population-level IFRs that are highest in HIC settings and lowest in LIC settings given the different demographics of these populations 15 . Second, we more realistically assume that health systems will be constrained to varying degrees. Here we follow the assumptions and parameters in Walker et al. 15 in which LIC and LMIC settings have limited hospital capacity (estimated using World Bank data) and that once exceeded, those requiring hospitalisation but who do not receive it experience worse outcomes. In contrast, in UMIC and HIC settings, while existing hospital capacity may also be exceeded, we assume that surge capacity is implemented to fill this gap. In LIC settings . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.19.21253960 doi: medRxiv preprint we additionally assume that outcomes for hospitalised cases are worse than in other settings. This results in slightly higher population-level IFRs in LIC and LMIC compared to UMIC and HIC settings 15 .

Our default assumption is that health system constraints are in place.

It is unlikely that relaxing NPIs would result in a return to the high level of transmission (R0 between values of 2 and 4) seen before controls were introduced, due to ongoing interventions (e.g. the use of facemasks, working from home and test/trace/isolate) 40 . We therefore explore three scenarios for Rt2 

We first consider optimal vaccine allocation within a country under different supply constraints. To do this, we divide the population into 5-year age groups and generate all possible age group combinations, where the selected age groups would then be allocated the vaccine. Since it is unlikely that multiple non-sequential 5-year age groups would be selected in any vaccine programme (for example, vaccinating only the 20-24-, 40-44-and 60-64-year-olds is not programmatically likely), we retain the age group combinations in which up to two contiguous "bands" of age groups could be selected. This would allow, for example, the elderly and children to be selected. The full set of age group combinations is described in the Supplementary Information (Section 1.6; Figure S3 ). For each combination we calculate the deaths averted over the time horizon, assuming 80% coverage (or uptake) of the vaccine within each 5-year age group and assuming default vaccine efficacy, duration, and coverage parameters, and with a 2020 epidemic that results in 11% of the HIC population being immune when the vaccine is introduced ( Table 1 ). The vaccine supply is calculated as the percentage of the total population who is vaccinated. We then select the most efficient allocation frontier from this set of simulations (see Supplementary Information, Figure S11 ). We compare this optimal strategy to two age-targeted approaches. In the first approach we sequentially allocate from the oldest age group downwards (80+ years, 75+, 70+ etc.), for both uniform vaccine efficacy across age groups and where efficacy in the 65+ group is reduced by 50%. In the second approach we target the working-age population, beginning with the highest risk group (60-64 years) and working downwards by age, and . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.19.21253960 doi: medRxiv preprint then sequentially add in the younger and older age groups either side of the working age population until the entire population is covered. We repeat this analysis for each income setting.

Second, we explore the impact of different global vaccine dose allocation strategies, assuming that the dose supply is constrained in 2021, with the dose constraint guided by the two billion doses that will be made available by the end of 2021 through the COVAX facility 43 . We use the same simulations as above to calculate the deaths averted in 2021 assuming default vaccine efficacy, duration, and coverage across the four income settings and for the set of 5-year age group combinations (Supplementary Information Section 1.6). We then calculate the total population-level impact in terms of deaths averted in the year 2021 for that income setting and age group, and use these results to quantify the total global impact and number of vaccine doses required for every combination of agetargeting strategies across the four income settings.

We then identify six plausible global vaccine allocation strategies, and simulate the health impact for each strategy, assuming a two-dose schedule, a 2 billion dose constraint, and 15% buffer stock and wastage (Table 1) :

• Strategy A: Countries are allocated doses relative to population size.

• Strategy B: Countries are allocated doses relative to population size, with individuals 65 years and older targeted first.

• Strategy C: Countries are allocated doses relative to size of population 65 years and older, with that age group targeted first.

• Strategy D: High-income countries can access doses first.

• Strategy E: Low-and lower-middle-income countries can access doses first.

• Strategy F: Countries are allocated the first 2 billion doses relative to population size, with additional doses available to high-and middle-income (UMIC and LMIC) countries (1.15 billion and 1.10 billion respectively, again distributed according to population).

For these six strategies, we do not stratify the population within an income setting into individual countries, therefore by extension we assume that doses can be distributed across any number of countries within an income setting, even if the dose supply means that coverage within an individual country is low.

We additionally use the ompr package in R 44 , which formulates and solves mixed linear integer optimisation problems, to identify the optimal global vaccine allocation strategy. To do this, we stratify the global population into the population sizes of the 85 largest countries (comprising 95% of the global population), assigning each country the characteristic age distribution, contact matrix, and . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.19.21253960 doi: medRxiv preprint health system capacity for its income setting to reduce computational requirements. Under this optimisation algorithm, the available doses can be allocated both between and within countries, thereby allowing different combinations of 5-year age groups to be selected within each country.

For both the fixed and optimal global vaccine allocation strategies, we calculate the total deaths averted per million population, and the deaths averted per 100 fully vaccinated persons, in order to compare the efficiency of the identified strategies.

We identify the optimal within-country and global between-country vaccine allocations, and calculate the impact of the six fixed global strategies (A-F), while varying our default parameter assumptions: vaccine efficacy reduced from 90% to 70%; efficacy in the 65 years and older population reduced by 50%; mode of vaccine action as disease-reducing only; greater NPIs following the introduction of a vaccine (implemented as Rt2 reduced from 2.0 to 1.5); reduced level of NPIs following the introduction of a vaccine (or higher transmission, implemented as Rt2 increased from 2.0 to 2.5); health system constraints assumed to be absent; infectiousness in children younger than 10 years reduced by 50%;

and life-years gained rather than deaths averted used as the global optimisation outcome measure.

Vaccines that are efficacious against infection can have health impact in two ways: by reducing the burden of disease through direct protection of those vaccinated, and by reducing infection, and therefore onward transmission, thus providing indirect protection to the entire population. For our assumed R0 of 2.5, the theoretical coverage required to achieve herd immunity for a 100% efficacious vaccine is 60%, in a population that mixes randomly. For a more transmissible strain (such as the recently identified new UK variant 45, 46 ) with an R0 of 4 the coverage required for herd immunity increases to 75%. Coverage must be higher if vaccine efficacy is below 100% (Figure 2A ). For example, for a vaccine with 90% efficacy the coverage would need to be 67% for R0=2.5 and 83% for R0=4.

However, as demonstrated in our simulations, temporary herd immunity can be reached at lower coverage levels since ongoing NPIs generate a lower effective reproduction number (illustrated here with R0=2). With wider vaccine availability from 2022 onwards it is likely that NPIs would gradually be lifted and hence higher coverage would be required to sustain herd immunity.

A vaccine that prevents infection has a greater impact than one of equivalent efficacy that prevents severe disease only due to the indirect effect of the former on transmission ( Figure 2B ). With an infection-reducing vaccine the projected deaths averted increases sharply with coverage until herd . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.19.21253960 doi: medRxiv preprint immunity is approached, at which point the curve plateaus. In contrast, a vaccine that only provides direct protection against disease has a linear relationship between coverage and health impact (deaths averted per thousand population). For example, for R0=2.5, Rt1=1.1, Rt2=2.0, vaccine efficacy of 90% and coverage of 67%, only approximately 60% of the deaths averted by an infection-reducing vaccine would be averted by a disease-reducing vaccine; this finding is consistent across income settings ( Figure S7 ). The additional value of indirect protection remains important for all potential vaccine efficacies and levels of coverage, as seen in the different slopes of the solid and dashed lines in Figure 2B . Similarly, the duration of protection will affect overall impact ( Figure S8 ) although this could be overcome through repeat vaccination.

The timing of vaccine introduction relative to the epidemic stage in each country will determine the additional health benefit that the vaccine generates. The health impact of the vaccine depends on the proportion of the population that have naturally acquired immunity at the time of vaccine introduction and the duration of that immunity. There is a clear decrease in public health impact with the extent of pre-existing immunity in the population, under the assumption that ongoing NPIs in 2021 do not differ based on this pre-existing immunity ( Figure 3A-B) . For example, we predict 6.0 deaths averted per 1,000 population up to the end of 2022 if only 4% of the population have pre-existing immunity compared to 3.9 if 14% of the population have pre-existing immunity. In addition, if vaccination is timely, its impact is greater in countries where other NPIs are not feasible, i.e. where Rt2 is higher ( Figure 3C -D). While our main analysis assumed that the target population is vaccinated before NPIs are lifted, if NPIs are lifted at vaccine introduction and that vaccination takes place over a longer period (one year), vaccine impact will be lower ( Figures 3E-F and S9 ). Furthermore, a greater public health impact will be obtained by targeting the older ages first rather than the working age population because the overall vaccine coverage during the period in which the epidemic occurs is lower compared to if NPIs are lifted after the target population is vaccinated.

The public health value of vaccination will also depend on the risk profile of the population and whether other therapeutic means are available to reduce morbidity and mortality. In the absence of any health system constraints, the public health value of a vaccine is predicted to be greatest in HIC since these countries have the largest elderly populations ( Figure 3G-H) . For example, we predict 3. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Even accounting for differences in demography, contact patterns and health system capacity, vaccination targeting those at highest risk of death is beneficial across all income settings. Given the strong age-gradient in the estimated IFR for SARS-CoV-2, here we illustrate the value of targeting by age (noting that similar principles will apply to other identified risk factors or vulnerable groups).

Under a strategy in which the most vulnerable age groups are targeted first, the required number of vaccine doses differs between income settings. This reflects the different age distributions, with relatively fewer doses required to fully cover the elderly populations in lower-income settings ( Figure   S10 ). The predicted public health impact of such a strategy is also highest in HIC, LMIC, and LIC settings, reflecting the overall higher IFR experienced in HIC countries and the presence of health system constraints in the LMIC and LIC settings. However, the impact of age prioritisation is substantially lower if the vaccine is less efficacious in the elderly population ( Figure 4B , 4D, 4F, 4H, Figure S13 , Table   S5 ). Figure 4A -H shows the most efficient allocation of the vaccine for each of the four country income settings. In all settings, if doses are limited, the most efficient approach is to vaccinate the most vulnerable elderly population, starting at the oldest age group and working downwards. In LIC settings, this approach broadly remains optimal throughout. However, in HIC, UMIC and LMIC settings we find that above a given threshold for dose availability and for a vaccine that reduces the risk of infection, the optimal allocation strategy switches from "direct protection of the vulnerable" to one of "herd impact", whereby the vaccine is allocated to younger populations (including children and adults).

Under such a scenario, transmission is reduced in the wider community and this indirectly reduces the risk to the vulnerable elderly population to a greater extent than through direct protection. Assuming that targeted age groups are vaccinated at 80% coverage, this switch occurs when there are sufficient doses to cover between 20% and 40% of the total population, although the precise value depends on both the relative size of the elderly population and on mixing patterns between the older population and the general population. Furthermore, in UMIC and LMIC settings we obtain a "mixed" approach at these intermediate dose availability levels, with both the highest risk elderly and younger populations included. This is due to greater mixing between the older and general populations in these settings, as well as the size of the high-risk older populations, which are generally smaller than in HIC settings. In all settings our optimisation includes the vaccination of children when this switch occurs.

Our model does not explicitly capture a lower transmission risk of children; if this is included, we find that they are de-prioritised ( Figure S18 ). The most efficient strategy is also sensitive to vaccine efficacy (where for a lower efficacy, the level of vaccine supply at which a herd impact strategy becomes optimal is higher, Figure S12 ). For a vaccine that reduces the risk of severe disease only, the optimal strategy is to directly protect the most vulnerable ( Figure S14 ). If NPIs are maintained at a greater level . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.19.21253960 doi: medRxiv preprint following vaccine introduction (explored by reducing Rt2 from 2.0 to 1.5), then we find that younger populations are targeted at a lower dose supply threshold (around 10%, Figure S15 ). Conversely, if transmission is higher (Rt2 increased from 2.0 to 2.5), it is efficient to continue to target older age groups even at a higher level of dose availability (Figure S16) .

At a global level and assuming an initial vaccine dose supply of 2 billion, allocating doses equitably across all income settings relative to population size (Strategy B), or relative to population size in the 65+ age group (Strategy C), are the most efficient of the fixed approaches considered, assuming that within a country the vaccine is targeted to the at-risk population ( Table 2 ). This finding is consistent across all sensitivity analyses considered (Table S6) (Table 3) , relative to 28%, 33% and 6% of global doses in UMIC, LMIC and LIC settings, respectively. This is due primarily to the older populations in HIC but is also dependent on absolute population sizes in each income band. Under the optimal allocation scenario, in LIC, LMIC and UMIC settings the proportional coverage is lower (between 8-10% coverage) and hence doses are targeted to the elderly population. Overall, assuming a vaccine reduces the risk of infection rather than only severe disease, the optimal allocation of 2 billion doses balances herd impact strategies in some countries with direct protection of the vulnerable in others.

The global optimised strategy is sensitive to assumptions about the vaccine mode of action, with a more equitable allocation found to be optimal for a vaccine that is efficacious against disease only . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (Table 3) . For a scenario with higher transmission following vaccine introduction relative to the default assumption, additional doses are allocated to HIC countries, however, for a scenario where NPIs are maintained to a greater extent following vaccination, a more equitable global allocation is optimal as the difference in averted deaths between income settings is less marked (Table 3, Figure S20 ). We also find that if life years gained, rather than deaths averted, is used as the outcome measure, doses are diverted away from UMICs and allocated to LMIC and LIC settings, whereas removing assumptions about health system constraints causes doses to be allocated preferentially to HIC and UMIC countries ( Table 3 , Figures S17 and S19 ).

An effective vaccine against SARS-CoV-2 will have enormous global public health and economic value.

As the leading candidate vaccines progress further through late-stage clinical trials and receive approval from government regulatory authorities, preparation is underway to scale up manufacturing capacity, supply chains, and delivery systems. This preparation should enable the first vaccines to be rapidly distributed in the coming year, however, it is unlikely that any candidate vaccine could be manufactured and distributed in sufficient quantity in 2021 to enable all countries to vaccinate their populations to achieve herd immunity. Furthermore, evidence on the extent to which the current vaccines are efficacious against infection (and therefore have potential to generate indirect protection) is still emerging from implementation studies, as phase III trials are generally not designed to measure this property. Current COVAX plans favour a global allocation strategy that prioritises the highest risk groups -including the elderly -and suggest an "equitable" vaccine allocation strategy in which each country receives doses in proportion to their population size and their epidemic status 7,47 .

Our results support such a strategy being close to optimal in terms of reducing the potential global mortality from SARS-CoV-2. Once all countries have been allocated doses to vaccinate 20% of the population, COVAX currently proposes that allocation of further doses should occur based on the epidemiological situation and local vulnerabilities. While we did not specifically explore this, our modelling framework can help support future prioritisation in the coming months.

For most infectious disease vaccines, one of the underlying goals is to vaccinate a sufficiently high proportion of the population to achieve herd immunity. Our results demonstrate that such indirect protection remains important for SARS-CoV-2 despite the strong risk-profile with increasing age.

Indirect protection has a particularly important benefit for vulnerable groups -such as the immunocompromised -who cannot be directly protected through vaccination. However, at a population level, the reduction in transmission that occurs also benefits those that receive the vaccine but who for whatever reason do not achieve sterile protection. The coverage required to achieve herd . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.19.21253960 doi: medRxiv preprint immunity will depend on both the underlying transmissibility of the virus (R0) and vaccine efficacy (the effective coverage) and requires a vaccine that is efficacious against infection rather than only disease.

For our assumed R0 of 2.5, the theoretical coverage required is 60% for a 100% efficacious vaccine.

Thus, for a vaccine efficacy of 90%, population coverage of nearly 70% would be required. It is possible that heterogeneity in contact rates could reduce this theoretical coverage if vaccination is targeted to those with the highest contact rates 48, 49 . Furthermore, in the presence of ongoing NPIs, the effective coverage required to interrupt transmission (i.e. to reduce Rt to less than 1) will be lower.

Nevertheless, aiming for high coverage will clearly be important given the uncertainty in the precise value of this threshold.

One of the challenges with quantifying the public health value of a SARS-CoV-2 vaccine is determining the appropriate "counterfactual" scenario against which its value can be assessed. Here we chose to generate some simplified scenarios that illustrate three factors determined by the epidemic to date: the proportion of the population with naturally acquired immunity, the likely forward trajectory of the epidemic in the absence of a vaccine, and the duration of both naturally acquired and vaccine-induced immunity. The interaction between these factors is predicted to generate complex immune landscapes 50 . The duration of vaccine-induced immunity is perhaps best addressed through repeat vaccination; however, it is important to note that such data will only become available after several months, and possibly years, of follow-up of trial participants. Similarly, pre-existing naturally acquired immunity is unlikely to be a barrier to immunisation, provided there are no vaccine-associated risks from antibody-dependent enhancement 51 . Thus, the value of vaccination should be quantified by the degree to which it enables NPIs to be lifted. Given the broader economic and societal costs of NPIs, combined epidemiological-economic models are required to address this.

We focused on two metrics to capture the public health value of the vaccine: deaths averted, and lifeyears gained. These metrics were chosen because the IFR is the best characterised endpoint and is easily translatable between settings. However, the impact of SARS-CoV-2 in terms of longer-term morbidity -so-called "Long COVID" 52 -could also be considerable. In health economics longer-term morbidity would normally be captured via Quality-Adjusted Life Years (QALYS). If morbidity is significant then it could favour the prioritisation of vaccination towards younger age-groups. However, at the current time, the extent and longer-term consequences of COVID-19 remain relatively poorly understood, with no other comparable respiratory infections available with which to quantify QALYs.

This will be a research priority in the coming months and years.

Several risk groups for more severe outcomes following SARS-CoV-2 infection have been identified, including individuals in some minority ethnic groups (although such studies are currently biased . CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.19.21253960 doi: medRxiv preprint towards countries with a majority White population) 53 ; those with obesity, who have a higher risk of a COVID-19 positive test, hospitalisation, and death 54 ; and those with other underlying health conditions 55 . However, age remains one of the strongest determinants of increased risk of mortality 56 .

Our results demonstrate that targeting a limited vaccine supply to older age groups is likely to be an efficient way from a public health perspective to reduce mortality if the number of available doses is insufficient to adopt a herd impact approach. However, even if sufficient doses of a vaccine that is efficacious against infection become available in 2021 to target vaccination to the working-age population to reduce transmission, if the early supply in the first quarter is constrained then targeting the most vulnerable will likely remain optimal. This result is consistent with other modelling studies that have considered either a full optimisation 57, 58 (in which a similar trade-off between direct protection and herd impact is observed) or sequential efficiency 59, 60 (in which the most vulnerable are initially prioritised). Such an approach also has the advantage that delivery systems are in place in many (though not all) settings that can access such groups. It is possible that for some vaccines the immune response in older individuals could be weaker; more data are required to characterise this effect for some products 2 . However, both the Pfizer/BioNTech and Moderna phase III trials demonstrated high efficacy in older age groups, providing further impetus for vaccinating older groups 4,5 .

One of the most difficult challenges facing decision-makers in 2021 will be the allocation of a limited dose supply. At the global level, under our baseline assumptions, the strategy that maximises the total deaths averted is one in which the available vaccine doses are allocated preferentially to higherincome countries who have the largest at-risk elderly populations but also have the strongest health systems. However, the optimality of this allocation is sensitive to many assumptions and will depend on both the vaccine characteristics and on the stage of the epidemic in each country throughout vaccine introduction. Considering the optimisation framework applied, it is possible that there are other dose allocation strategies that would be close to the optimal solution, but that distribute doses between countries in the same income setting differently. Given this uncertainty, allocating vaccine doses according to population size appears to be the next most efficient approach.

Within a country, the most efficient strategy for individual countries will generally be to prioritise is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.19.21253960 doi: medRxiv preprint recovery, it would rely on all vaccine doses being immediately available and able to be administered while NPIs are maintained, therefore the optimality of targeting younger groups may not hold if vaccines are delivered in a gradual phased approach. Also, this approach requires a higher dose supply if transmission is higher, indicating that in the presence of new variant strains, prioritising vaccination of the most vulnerable groups will likely remain the most appropriate strategy.

In our study we assessed the impact of vaccination for broad income strata, rather than individual countries. Decision-making at the individual country level will need to account for local epidemic history, levels of transmission, other control measures and how long they can be sustained, and the sizes of the populations at highest risk within those settings 55 . Some countries have identified prioritisation frameworks for allocating vaccines, with general agreement that frontline health care workers and high-risk populations should be allocated the first available doses, and our user-friendly COVID-19 vaccine simulation interface could help in supporting such decisions about country-level introductions (Box 1). However, there are many other setting-specific factors that will also be important for governments to consider, including supply chains, logistics, access to populations, costs and budgets, and competing health, economic, and social priorities 14 .

As with any modelling study, there are several limitations to our approach. First, while phase III trial efficacy results have been announced for several vaccine candidates, durability data are not yet available, and data on the extent to which the current vaccine products can prevent infection are still emerging 2,3,28 ; our model assumptions may therefore need to be updated as trials and effectiveness studies progress. Second, the number of doses and the timing of their availability are also uncertain;

for this reason, we have illustrated simplified scenarios in which vaccination occurs over a one-month period for a range of epidemic stages. In practice, each country will have experienced a different epidemic when the first vaccine is introduced and will scale up coverage over a period of months. Third, the model used here is relatively simple in structure and can only simulate the impact of a single vaccine product, with one value for average vaccine efficacy, meaning we could not include complexities such as multiple vaccine products, nor the potential partial efficacy following the first dose in a multi-dose vaccine schedule. These considerations will be important for future studies.

Fourth, our study focuses only on the health benefits of vaccination. It will also be important to consider other therapeutic interventions, as well as the capacity of countries to suppress transmission using NPIs, and to better capture specific risk groups as appropriate to individual countries. Furthermore, the direct health outcome is only one dimension; it will be important in the near-term to capture the impact of vaccination on non-COVID-19 health, as well as to integrate epidemiological and economic models to evaluate the impact of different vaccine allocation strategies on the economic outputs of countries and the livelihoods of their citizens. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Research and development of a SARS-CoV-2 vaccine has taken place at unprecedented speed, with efficacy and safety results now available for several vaccine candidates within one year of the pandemic being declared. Our results demonstrate that the global public health value of the vaccine can be maximised by ensuring equitable access. Acting collectively in this way during the early stages of vaccine deployment remains the ethical approach to take, even if this is not the most beneficial short-term strategy from a national perspective. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Table 3 : Identified Optimal Global Allocation by Income Setting. The optimal allocated coverage is the fully vaccinated persons per population, and the value in parentheses represents the proportion of total global doses allocated to that income setting. The Default scenario represents the default vaccine assumptions in Table 1 . We also present the sensitivity of the allocation to changes in the assumptions about vaccine efficacy, vaccine efficacy in the 65+ years age group, mode of action of the vaccine, NPIs at vaccine introduction, health system constraints, reduced infectiousness in children younger than 10 years, and life-years gained (LYG) as an optimisation measure. The within-setting results are shown in Figures S12-S19, and the public health impact for each scenario is in Table S5 .

The estimated proportion of the global population in each income setting is included for reference. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint (Table S3 ). Impact is shown for a HIC setting and all age groups are vaccinated uniformly; additional plots for other income settings and health system constraint assumptions are in Figure S7 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Table 1 . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.19.21253960 doi: medRxiv preprint additional age groups (75-79, 70-74 and so on) as additional doses are available. The turquoise points show the same strategy, but where vaccine efficacy in the 65+ population is 35% (immunosenescence). The green points show the strategy that prioritises the working age population first (beginning with the 60-64 age group and sequentially adding younger groups), then vaccinates the elderly and children as doses become available. Health system constraints in LICs and LMICs are assumed to be present These allocations are generated using the default vaccine characteristics in Table 1 , with 80% coverage in the target age group vaccinated; additional scenarios are shown in Figures S12-S19.

. CC-BY 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted March 20, 2021. ; https://doi.org/10.1101/2021.03.19.21253960 doi: medRxiv preprint

COVID-19 vaccine tracker

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Ensuring global equitable access to COVID-19 vaccines

US buys nearly all of Gilead's Covid-19 drug remedesivir

Government says medicines must be stock-piled for no-deal Brexit on top of Covid-19 pressures

World Health Organization. Ethics and COVID-19: resource allocation and priority-setting

Principles for allocation of scarce medical interventions

Estimates of the severity of coronavirus disease 2019: a model-based analysis

Who should be prioritised for COVID-19 vaccination?

The impact of COVID-19 and strategies for mitigation and suppression in low-and middle-income countries

The World Bank. DataBank World Development Indicators

United Nations World Population Prospects

(ICNARC) ICNA& RC. ICNARC report on COVID-19 in critical care 16

Estimating the burden of SARS-CoV-2 in France

Report 34 -COVID-19 Infection Fatality Ratio estimates from seroprevalence

An interactive web-based dashboard to track COVID-19 in real time

Immunosenescence: Influenza vaccination and the elderly

Estimating Direct and Indirect Protective Effect of Influenza Vaccination in the United States

Beigel for the mRNA-1273 SG. An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Articles Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1 / 2 , single-blind , randomised controlled trial

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, nonrandomised, first-in-human trial

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Instituto de Salud Carlos III. Estudio Nacional de Sero-Epidemiolgia de la Infeccion por SARS-CoV-2 en Espana: Informe Final

COVID-19 re-infection by a phylogenetically distinct SARScoronavirus-2 strain confirmed by whole genome sequencing

Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study)

MRC Centre for Global Infectious Disease Analysis Imperial College London. Future scenarios of the healthcare burden of COVID-19 in Low-or Middle-income countries

Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980-2016: A systematic analysis for the Global Burden of Disease Study

An ethical framework for global vaccine allocation

World Health Organization. 172 countries and multiple candidate vaccines engaged in COVID-19 vaccine Global Access Facility

Estimated transmissibility and severity of novel SARS-CoV-2 Variant of Concern 202012/01 in England

Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data

92 low-and middle-income economies eligible to get access to COVID-19 vaccines through Gavi COVAX AMC

A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2

COVID-19 herd immunity: where are we?

Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years

Immunological considerations for COVID-19 vaccine strategies

Covid-19: What do we know about 'long covid'?

Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis

Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships

Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study

Vaccine optimization for COVID-19, who to vaccinate first?

Prioritising COVID-19 vaccination in changing social and epidemiological landscapes

Epidemiological Impact of SARS-CoV-2 Vaccination: Mathematical Modeling Analyses

Modelling optimal vaccination strategy for SARS-CoV-2 in the UK

The Optimal Allocation of Covid-19 Vaccines

Allocation of COVID-19 Vaccines Under Limited Supply

Model-informed COVID-19 vaccine prioritization strategies by age and serostatus

Covid-19: Global attitudes towards a COVID-19 vaccine

Articles Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020 : a population-level observational study

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection